Alzheimer's disease, a devastating neurodegenerative condition that affects millions of people worldwide, may have found a ...

DelveInsight’s, “Peripheral Arterial Disease Pipeline Insight 2024” report provides comprehensive insights about 18+ ...

MONCYTE Health, a diagnostics company based in Helsinki, has raised €1 million in a seed funding round to advance its ...

For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

and thus were more likely to receive prescriptions for diuretics and lipid-lowering drugs.

Obicetrapib was tested as a monotherapy and in combination with lipid-lowering medications like statins. The topline results from the pivotal BROOKLYN trial were announced in July 2024.

The increasing use of drugs and alcohol by pregnant women has resulted in a population of children with unique neurodevelopmental behaviors. Of 223 children evaluated in a multidisciplinary child ...

This study aimed to assess the causal relationship between genetically proxied lipid-lowering drugs and skin cancers and psoriasis. Methods: Two-sample Mendelian randomization (MR) analysis was ...